JAMA Cardiology

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023

Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.

Key Points: 
  • Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.
  • In July 2023, LianBio entered into a clinical supply agreement with AstraZeneca in China to procure osimertinib for this clinical trial.
  • In October 2023, LianBio announced that the company’s Board of Directors initiated a comprehensive strategic review of the company, with an update anticipated in the first half of 2024.
  • Cash, cash equivalents, marketable securities and restricted cash at September 30, 2023 totaled $252.2 million compared to $302.4 million as of December 31, 2022.

Association of Black Cardiologists Awards Over $125,000 in Scholarships to Promising Minority Medical Students

Retrieved on: 
Tuesday, October 24, 2023

WASHINGTON, Oct. 24, 2023 /PRNewswire/ -- The Association of Black Cardiologists (ABC) will award scholarships to fifteen minority medical students from across the country.

Key Points: 
  • WASHINGTON, Oct. 24, 2023 /PRNewswire/ -- The Association of Black Cardiologists (ABC) will award scholarships to fifteen minority medical students from across the country.
  • Of the students selected this year, five will receive the Dr. Richard Allen Williams Scholarship for Medical Students and ten have been chosen to receive the ABC/Biosense Webster Scholarship for Medical Students .
  • ABC established the first scholarship for medical students of color in 1984, named after its founder, Dr. Williams, as part of its workforce diversity initiatives to support future cardiologists.
  • Additionally, a report from the Association of American Medical Colleges (2019) found that less than 4% of medical school faculty are Black.

LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology

Retrieved on: 
Monday, August 28, 2023

Mavacamten also demonstrated improvement across all secondary endpoints, including LVOT obstruction, clinical symptoms, and health status.

Key Points: 
  • Mavacamten also demonstrated improvement across all secondary endpoints, including LVOT obstruction, clinical symptoms, and health status.
  • The data presented at ESC 2023 and published in JAMA Cardiology continue to demonstrate robust evidence of mavacamten’s therapeutic benefit.
  • As previously reported, safety results in the trial were consistent with previous studies of mavacamten in symptomatic oHCM, and no new safety signals were reported.
  • “The EXPLORER-CN trial demonstrates that the well-established therapeutic benefit of this drug also extends to Chinese patients.

Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

Retrieved on: 
Monday, August 28, 2023

Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
  • Overall, 75.9% of patients improved by ≥1 NYHA class from baseline at the start of the LTE study to Week 120.
  • Of the 14 patients who were in NYHA class I, 12 remained in NYHA class I at the latest available assessment.
  • “Studies like EXPLORER-LTE are important for understanding longer-term results that assess key cardiac measures and support the use of CAMZYOS in patients living with this chronic condition.”

HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board

Retrieved on: 
Tuesday, June 20, 2023

HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, today announced that Douglas L. Mann, M.D.

Key Points: 
  • HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, today announced that Douglas L. Mann, M.D.
  • is joining as Chairperson of the company’s Clinical Advisory Board.
  • is joining as Chairperson of the company’s Clinical Advisory Board.
  • Members of HAYA’s Clinical Advisory Board:
    “Through their platform, HAYA developed HTX-001, a targeted fibrosis-modifying therapy for heart failure.

ReCor Medical Announces Two Concurrent JAMA Network Publications of Study Results on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Tuesday, February 28, 2023

Study results showed that the Paradise Ultrasound Renal Denervation (uRDN) System successfully reduced blood pressure compared to sham.

Key Points: 
  • Study results showed that the Paradise Ultrasound Renal Denervation (uRDN) System successfully reduced blood pressure compared to sham.
  • Results of the pooled analysis showed a consistent blood pressure lowering effect across a broad range of hypertension, including mild to moderate and resistant hypertension.
  • RADIANCE II is a randomized, sham-controlled US FDA IDE pivotal trial of the Paradise uRDN System in the treatment of patients with uncontrolled hypertension.
  • “ReCor is focused on bringing the Paradise uRDN System to patients and their physicians as a treatment option in the near future.”

Caption Health Receives Regulatory Approvals for Caption AI™ Technology Platform in Canada and Australia

Retrieved on: 
Thursday, November 10, 2022

BRISBANE, Calif., Nov. 10, 2022 /PRNewswire/ -- Caption Health, the leader in using AI and services to improve access to heart ultrasound diagnostics, announced new regulatory approvals to market its Caption AI™ technology platform from Health Canada's Medical Devices Directorate and Australia's Therapeutic Goods Administration. Echocardiography is the preferred initial imaging modality for evaluation of patients with suspected heart failure, and Caption Health expects its global growth will enable widespread access to earlier and more accurate cardiac care, especially within underserved populations and regions, as it has begun to do in the U.S.

Key Points: 
  • BRISBANE, Calif., Nov. 10, 2022 /PRNewswire/ -- Caption Health , the leader in using AI and services to improve access to heart ultrasound diagnostics, announced new regulatory approvals to market its Caption AI technology platform from Health Canada's Medical Devices Directorate and Australia's Therapeutic Goods Administration.
  • These are the second and third international regulatory approvals this year for Caption AI, following this summer's European CE Mark announcement.
  • "Our strategic global expansion is about more than market access, it's about patient access," said Steve Cashman, CEO of Caption Health.
  • The company's Caption Care services offer health providers, payers, and value-based care organizations convenient and cost-effective echos for their members, leveraging its Caption AI technology platform.

Saranas Announces Over 1,200 Patients Treated with the Early Bird® Bleed Monitoring System

Retrieved on: 
Wednesday, November 9, 2022

Saranas, Inc. announced today that over 1,200 patients have been treated with the Early Bird Bleed Monitoring System, the first and only FDA-approved bleed detection system.

Key Points: 
  • Saranas, Inc. announced today that over 1,200 patients have been treated with the Early Bird Bleed Monitoring System, the first and only FDA-approved bleed detection system.
  • The adoption of the Early Bird system is a testimony to physicians embracing the benefits of early bleed detection for their patients and practice.
  • The Early Bird Bleed Monitoring System includes a bleed detection array with integrated electrodes in a fully functional vascular access sheath.
  • First-in-Human Study of the Saranas Early Bird Bleed Monitoring System for the Detection of Endovascular Procedure-Related Bleeding Events.

Caption Health and Heartbeat Health partner to provide unprecedented access to cardiac care

Retrieved on: 
Thursday, July 28, 2022

BRISBANE, Calif. and NEW YORK, July 28, 2022 /PRNewswire/ -- Caption Health, the leader in providing services and AI to improve heart ultrasound access, and Heartbeat Health, the nation's largest Virtual Cardiology company, today announced a partnership that will enable providers to offer their patients earlier access to cardiovascular care than ever before possible. In this partnership, Caption Health's Caption Care™ clinicians will perform heart ultrasounds in convenient locations, even a patient's home, using the Caption AI platform, while Heartbeat Health virtual cardiologists receive, read, and interpret the ultrasounds remotely through their telemedicine platform. Heartbeat will then provide televisits and discuss findings with primary care teams for patients with abnormal cardiac findings via their virtual programs.

Key Points: 
  • Heartbeat will then provide televisits and discuss findings with primary care teams for patients with abnormal cardiac findings via their virtual programs.
  • Together, the partners are increasing access to early cardiac evaluations and care by providing these two innovations as a value-based bundle for health providers, payers, and value-based care organizations.
  • Limited access to cardiac diagnosis and care has long contributed to health disparities between regions and communities, a problem exacerbated by the pandemic.
  • The company's Caption Care services offer health providers, payers, and value-based care organizations convenient and cost-effective echos for their members, leveraging its Caption AI technology platform.

Caption Health Receives CE Mark for Caption AI™ technology platform

Retrieved on: 
Tuesday, July 19, 2022

BRISBANE, Calif., July 19, 2022 /PRNewswire/ -- Caption Health, the leader in using AI and services to improve heart ultrasound access, today announced that it has received a CE Mark for its Caption AI™ technology platform. This certification represents the first step in making Caption Health's industry-leading technology platform available outside the US, and highlights the company's strong clinical and regulatory track record as it uses AI and ultrasound to deliver better cardiac care.

Key Points: 
  • BRISBANE, Calif., July 19, 2022 /PRNewswire/ -- Caption Health , the leader in using AI and services to improve heart ultrasound access, today announced that it has received a CE Mark for its Caption AI technology platform.
  • Caption Health is making earlier cardiac care accessible wherever patients are, utilizing the Caption AI platform to provide a convenient, cost-effective solution for cardiac ultrasound, the primary tool for assessing heart failure.
  • Caption Health has developed the AI platform that enables heart ultrasound access for early disease detection when there is the highest potential for impact.
  • The company's Caption Care services offer health providers, payers, and value-based care organizations convenient and cost-effective echos for their members, leveraging its Caption AI technology platform.